Contact

Mark Salvati
www.linkedin.com/in/mark- Vice President Global Program Head, Translational and Clinical
salvati-0b10054 (LinkedIn) Oncology at Regeneron
Los Angeles Metropolitan Area
Top Skills
Biomarkers Summary
Oncology
Single point of contact to lead cross function early development
Clinical Development
teams in Oncology. Development of Amgen Immuno-Oncology
portfolio through the NME to Phase 1/2 space with focus on CAR-T
and T-Cell redirections agents in the solid tumor space.

Experience
Regeneron
Vice President
March 2022 - Present (1 year 8 months)
United States

Development lead for Anti-LAG3 Antibody Fianlimab (REGN3767) and Anti-

GITR Antibody (REGN6569) programs

Amgen
Global Product General Manager, Oncology Early Development Lead
March 2018 - Present (5 years 8 months)
Thousand Oaks, California

Single cross functional point of contact leading global early development of

Immuno-Oncology agents in Amgen portfolio. Focus on application of CAR-T
and T-Cell redirection agents for the treatment of solid tumor indication in the
NME to Phase 1/2 space.

Janssen Inc.
Compound Development Team Lead, Senior Director
January 2015 - March 2018 (3 years 3 months)
Spring House, PA

Cross function single point of accountability early compound development

lead. Leading early and late clinical development programs in IO space with
a focus on novel innate immune activator targets as well as T-Cell and NK
Cell redirect agents for the treatment of Heme and solid tumor malignancies.
Development of novel epigenetic modifying agents for treatment of Heme and

Page 1 of 2
solid tumor indications. Lead and execute Business Development programs to
in license new develop assets and out license internal assets

Bristol-Myers Squibb
6 years 10 months

Group Director, Oncology Global Clinical Research

August 2014 - January 2015 (6 months)
Princeton, New Jersey

Excution of registrational trials for the Nivolumab program in NSCLC area

Group Director, Oncology Global Medical, Nivolumab

October 2013 - August 2014 (11 months)

Medical Director, Oncology Global Medical Affairs, anti-PD-1

February 2012 - October 2013 (1 year 9 months)
Princeton, New Jersey

Medical Affairs strategy lead for global development of anti-program cell

death-1 (anti-PD-1) and anti-PD-L1 programs in NSCLC, Melanoma, mRCC
and LCM. Member of Immuno-Oncology team and Lung Cancer Tumor
Strategy Group.

Medical Director, Erbitux US Medical Affairs

July 2010 - February 2012 (1 year 8 months)

Ixebepilone Medical Lead, Global Medical Affairs

April 2008 - July 2010 (2 years 4 months)

Bristol-Myers Squibb
Group Leader CV
January 2006 - January 2008 (2 years 1 month)

Wyeth
Group leader
1992 - 1998 (6 years)

Education
University of California, Los Angeles
Doctor of Philosophy (Ph.D.), Organic Chemistry · (1987 - 1992)

Page 2 of 2